Colorectal Cancer Dataset in Xijing Hospital From 2011

NCT06308354 | Recruiting

• 1 other identifier: CRC dataset
• Study Type: observational
• Target: 40,000
• Locations: 1 country
• Sites: 1

Brief Summary

To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.

Conditions

Prognostic Cancer Model; Chemotherapy; Nutrition Related Cancer

Outcome Measures

Primary Outcomes (2)

• overall survival

  to dead or lost to follow

  from date of diagnosis until the date of death from any cause, assessed up to 120 months

• DFS

  disease-free survival

  from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months

Study Arms (1)

colorectal cancer

Colorectal cancer patients are enrolled when patients were underwent surgeries.

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Colorectal cancer patients mainly comes from the western areas of China, and would accept the surgical procedures. Participate would be followed up every 6 months after surgery.

You may qualify if:

• \. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;
• \. Visit our center with complete medical records and pathological information;
• \. Colorectal cancer patients diagnosed between 2013 and 2023.

You may not qualify if:

• \. The patient has other colorectal malignancies other than adenocarcinoma;
• \. Malignant tumors adjacent to organs invading the colon and rectum;
• \. Malignant tumors from distant organs metastasize to the colon and rectum;
• \. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.

Sponsors & Collaborators

• Xijing Hospital: lead

Study Sites (1)

Fourth Military Medical University

Xi'an, Shaanxi, China

RECRUITING

Related Publications (1)

• Cao S, Qiao Y, Wu L, Chen Q, Tian K, Li J, Xing C. Postoperative adjuvant chemotherapy in patients with stage II early onset colorectal cancer: exploration and discovery using real-world data and the SEER database. Front Oncol. 2025 May 30;15:1566569. doi: 10.3389/fonc.2025.1566569. eCollection 2025.

  PMID: 40519292 DERIVED

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 18, 2024
• First Posted: March 13, 2024
• Study Start: January 1, 2011
• Primary Completion (Estimated): January 1, 2048
• Study Completion (Estimated): January 1, 2048
• Last Updated: March 13, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)